Preservation of nephron number during the active trial period might conceivably reduce hyperfiltration and risk of ESKD, and preservation of kidney function may have mediated some of the post-trial observed benefits on cardiovascular death.11 The acute eGFR dip with SGLT2 inhibition reversed within 4 weeks after discontinuation,12,13 so some of the observed post-trial benefit on eGFR components of kidney disease progression could result from reversal of the acute eGFR dip after cessation of study drug. This evidence concerns the gene SLC5A2 and kidney disorder.